cervical cancer Cervical carcinoma
Conditions
Interventions
None listed
Sponsors
Verloskunde en Gynaecologie, subafdeling Gynaecologie en Gynaecologische Oncologie, Erasmus MC, Daniel den Hoed
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: • Cervical cancer patients with a routine indication for primary treatment combined with hyperthermia • Tumor lesions amendable for biopsies • Age >18 years • Platelets >100 x 10e9/L • Written informed consent
Exclusion criteria
Exclusion criteria: • Current therapeutically use of anti-coagulant (coumarin, warfarin, heparin or low molecular weight heparin [LMWH]). LMWH if used for prophylaxis is allowed. • Any psychological condition potentially hampering compliance with the study protocol. • Patients who are treated in another institution for radiotherapy, with more than 2 hour travel distance.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The level of BRCA2 protein as detected by immuno (Western) blotting with anti-BRCA2 antibody before and after hyperthermia as a measure of homologous recombination (HR) deficiency. In parallel, part of the pre-hyperthermia obtained tumor cells will be incubated at 37*C or 41*C in the laboratory, as an ex vivo control experiment in the same patient. | — |
Secondary
| Measure | Time frame |
|---|---|
| The presence of CTC before and after hyperthermia treatment. | — |
Countries
Netherlands
Outcome results
None listed